In vivo studies using mouse models have demonstrated that PARP inhibitors are effective against IDH mutant myeloproferative syndrome (MDS)/AML and can overcome resistance to targeted IDH inhibitors [152]. This evidence concerns the gene IDH2 and myelodysplastic syndrome.